 Jacob Gadwa
Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2024 | 527 | 2.680 |
Why?
| | Tumor Microenvironment | 9 | 2025 | 588 | 1.030 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2023 | 377 | 0.850 |
Why?
| | Interleukin-2 | 2 | 2023 | 427 | 0.820 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2021 | 30 | 0.720 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 44 | 0.700 |
Why?
| | Receptors, Complement | 1 | 2021 | 120 | 0.700 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2025 | 264 | 0.660 |
Why?
| | Ephrin-B2 | 4 | 2024 | 50 | 0.640 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 203 | 0.630 |
Why?
| | Receptor, EphB4 | 3 | 2024 | 36 | 0.600 |
Why?
| | Complement Activation | 1 | 2020 | 359 | 0.560 |
Why?
| | Pancreatic Neoplasms | 4 | 2025 | 878 | 0.470 |
Why?
| | Immunotherapy | 5 | 2025 | 579 | 0.410 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3100 | 0.370 |
Why?
| | Mice | 15 | 2025 | 16543 | 0.330 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 76 | 0.310 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 312 | 0.310 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 290 | 0.300 |
Why?
| | Animals | 16 | 2025 | 34628 | 0.270 |
Why?
| | Neoplasms | 1 | 2020 | 2426 | 0.250 |
Why?
| | Cell Proliferation | 3 | 2021 | 2337 | 0.230 |
Why?
| | PPAR alpha | 1 | 2024 | 58 | 0.230 |
Why?
| | Oleic Acid | 1 | 2024 | 38 | 0.220 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2024 | 38 | 0.220 |
Why?
| | Interleukin-7 | 1 | 2024 | 58 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 187 | 0.210 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2024 | 190 | 0.210 |
Why?
| | Tumor Burden | 2 | 2021 | 284 | 0.210 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 166 | 0.210 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 42 | 0.200 |
Why?
| | Cigarette Smoking | 1 | 2023 | 90 | 0.200 |
Why?
| | Radioimmunotherapy | 1 | 2021 | 14 | 0.190 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1230 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Mycobacteriophages | 1 | 2020 | 2 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 52 | 0.180 |
Why?
| | Radiation Tolerance | 1 | 2021 | 97 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.170 |
Why?
| | Tuberculosis | 1 | 2023 | 271 | 0.170 |
Why?
| | Rifampin | 1 | 2020 | 82 | 0.170 |
Why?
| | Mice, Knockout | 3 | 2021 | 2770 | 0.170 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 182 | 0.170 |
Why?
| | Complement C3 | 1 | 2021 | 200 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 139 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 170 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 316 | 0.160 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 347 | 0.160 |
Why?
| | Humans | 18 | 2025 | 128896 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 170 | 0.160 |
Why?
| | Antitubercular Agents | 1 | 2020 | 195 | 0.160 |
Why?
| | Dexamethasone | 1 | 2021 | 330 | 0.150 |
Why?
| | Fibrosis | 1 | 2021 | 518 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2024 | 824 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2021 | 1100 | 0.150 |
Why?
| | Dendritic Cells | 1 | 2021 | 478 | 0.140 |
Why?
| | Glioblastoma | 1 | 2020 | 311 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5270 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 732 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2022 | 895 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1312 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1170 | 0.110 |
Why?
| | Signal Transduction | 2 | 2024 | 4857 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6568 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2022 | 1213 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 928 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 797 | 0.070 |
Why?
| | Cell Movement | 2 | 2021 | 932 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 1884 | 0.060 |
Why?
| | Fenofibrate | 1 | 2024 | 30 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 608 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3787 | 0.050 |
Why?
| | Female | 3 | 2025 | 68162 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 166 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2481 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 69 | 0.050 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 25 | 0.050 |
Why?
| | Fatty Acids | 1 | 2024 | 415 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 225 | 0.050 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.050 |
Why?
| | Nicotine | 1 | 2023 | 303 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 129 | 0.040 |
Why?
| | Luciferases | 1 | 2020 | 148 | 0.040 |
Why?
| | Luminescent Measurements | 1 | 2020 | 78 | 0.040 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2020 | 56 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 383 | 0.040 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2020 | 135 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 479 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 680 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 422 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2021 | 400 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1040 | 0.040 |
Why?
| | Phosphorylation | 1 | 2020 | 1685 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 802 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2603 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 3994 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1905 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3059 | 0.030 |
Why?
|
|
Gadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|